Perioperative Management of Anticoagulants

  • Ibrahim M. Ali
  • Alexander Volodarskiy
  • Joe F. Lau


It is estimated that 250,000 patients who are on anticoagulants undergo surgery annually. Management of anticoagulant and antiplatelet therapies in patients scheduled for surgery is challenging, as the interruption of therapy may increase the risk of thromboembolism, and continuation may predispose patients to increased peri- and intraoperative bleeding risks. It is therefore crucial to conduct an individualized and thorough periprocedural assessment for risk of thromboembolism and bleeding. This chapter will outline the management of warfarin, direct oral anticoagulants, and antiplatelet agents in the perioperative setting. Topics such as short-term parenteral or “bridging” therapy, bleeding risk stratification, and thromboembolic risk stratification will be addressed.


Parenteral anticoagulation Perioperative CHA2DS2-VASc HAS-BLED Warfarin Direct oral anticoagulants (DOACs) Antiplatelet Venous thromboembolism (VTE) Arterial thromboembolism (ATE) Atrial fibrillation Prosthetic heart valve 


  1. 1.
    Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012;126(13):1573–6.CrossRefGoogle Scholar
  2. 2.
    Guyatt GH, Akl EA, Crowther M, Schunemann HJ, Gutterman DD, Zelman Lewis S, et al. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):48S–52S.CrossRefGoogle Scholar
  3. 3.
    Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):299S–339S.CrossRefGoogle Scholar
  4. 4.
    Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954–62.CrossRefGoogle Scholar
  5. 5.
    Dincq AS, Lessire S, Douxfils J, Dogne JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int. 2014;2014:385014.CrossRefGoogle Scholar
  6. 6.
    Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S–50S.CrossRefGoogle Scholar
  7. 7.
    Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506–11.CrossRefGoogle Scholar
  8. 8.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.CrossRefGoogle Scholar
  9. 9.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983.CrossRefGoogle Scholar
  10. 10.
    Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke. 1996;27:1760–4.CrossRefGoogle Scholar
  11. 11.
    Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–92.CrossRefGoogle Scholar
  12. 12.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285(22):2864–70.CrossRefGoogle Scholar
  13. 13.
    Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 2012;125(6):603.e1–6.CrossRefGoogle Scholar
  14. 14.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRefGoogle Scholar
  15. 15.
    Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL Jr, Ortel TL, Saxonhouse SJ, Spinler SA. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69(7):871–98.CrossRefGoogle Scholar
  16. 16.
    Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.CrossRefGoogle Scholar
  17. 17.
    Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.CrossRefGoogle Scholar
  18. 18.
    Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65(3):25–32.CrossRefGoogle Scholar
  19. 19.
    Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.CrossRefGoogle Scholar
  20. 20.
    Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.CrossRefGoogle Scholar
  21. 21.
    Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658–63.CrossRefGoogle Scholar
  22. 22.
    Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prosthesis. Circulation. 1994;89:635–41.CrossRefGoogle Scholar
  23. 23.
    Andersen PV, Alstrup P. Long-term survival and complications in patients with mechanical aortic valves without anticoagulation. A follow-up study from 1 to 15 years. Eur J Cardiothorac Surg. 1992;6(2):62–5.CrossRefGoogle Scholar
  24. 24.
    McKenzie DB, Wong K, Edwards T. The management of patients with mechanical heart valves and intracerebral haemorrhage. Br J Cardiol. 2008;15:145–8.Google Scholar
  25. 25.
    Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med. 2009;76(Suppl 4):S37–44.CrossRefGoogle Scholar
  26. 26.
    Perry DJ, Noakes TJ, Helliwell PS. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203(7):389–93.CrossRefGoogle Scholar
  27. 27.
    Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, et al. Standards of Practice Committee with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009;20(7 Suppl):S240–9.CrossRefGoogle Scholar
  28. 28.
    Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM, European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27(12):999–1015.CrossRefGoogle Scholar
  29. 29.
    Horlocker TT. Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy. Br J Anaesth. 2011;107(Suppl 1):i96–106.CrossRefGoogle Scholar
  30. 30.
    Zaca V, Marcucci R, Parodi G, Limbruno U, Notarstefano P, Pieragnoli P, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6):840–54.CrossRefGoogle Scholar
  31. 31.
    Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40(3):182–212.CrossRefGoogle Scholar
  32. 32.
    Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206–32.CrossRefGoogle Scholar
  33. 33.
    Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):187–205.CrossRefGoogle Scholar
  34. 34.
    ASGE Standards of Practice Committee, Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, Eloubeidi MA, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3–16.CrossRefGoogle Scholar
  35. 35.
    Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith L-A, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016;48(4):c1.PubMedGoogle Scholar
  36. 36.
    Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. Br J Anaesth. 2013;111(Suppl 1):i3–17.CrossRefGoogle Scholar
  37. 37.
    Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol. 2008;140(5):496–504.CrossRefGoogle Scholar
  38. 38.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DEA. new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401.CrossRefGoogle Scholar
  39. 39.
    Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9.CrossRefGoogle Scholar
  40. 40.
    Pisters RLD, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefGoogle Scholar
  41. 41.
    Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012;108(1):65–73.CrossRefGoogle Scholar
  42. 42.
    Link KP. The discovery of dicumarol and its sequels. Circulation. 1959;19(1):97–107.CrossRefGoogle Scholar
  43. 43.
    Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–11.CrossRefGoogle Scholar
  44. 44.
    Campbell HA, et al. Studies on the hemorrhagic sweet clover disease. J Biol Chem. 1940;136:47–55.Google Scholar
  45. 45.
    Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011;117(19):5044–9.CrossRefGoogle Scholar
  46. 46.
    Syed S, Adams BB, Liao W, Pipitone M, Gloster H. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol. 2004;51(6):955–7.CrossRefGoogle Scholar
  47. 47.
    Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res. 2009;124(3):292–9.CrossRefGoogle Scholar
  48. 48.
    Linkins L, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893–900.CrossRefGoogle Scholar
  49. 49.
    Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332(25):1661–5.CrossRefGoogle Scholar
  50. 50.
    Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–77.CrossRefGoogle Scholar
  51. 51.
    Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135(10):e604–e33.CrossRefGoogle Scholar
  52. 52.
    Makaryus JN, Halperin JL, Lau JF. Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol. 2013;10(7):397–409.CrossRefGoogle Scholar
  53. 53.
    Imberti D, Ambrosoli A, Cimminiello C, Compagnone C, Fanelli A, Tripodi A, et al. Periprocedural management of rivaroxaban-treated patients. Expert Opin Pharmacother. 2015;16(5):685–91.CrossRefGoogle Scholar
  54. 54.
    Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(5):711–9.CrossRefGoogle Scholar
  55. 55.
    Di Minno MN, Milone M, Mastronardi P, Ambrosino P, Di Minno A, Parolari A, et al. Perioperative handling of antiplatelet drugs. A critical appraisal. Curr Drug Targets. 2013;14(8):880–8.CrossRefGoogle Scholar
  56. 56.
    Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the US Preventive Services Task Force. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville: Agency for Healthcare Research and Quality (US); 2009.Google Scholar
  57. 57.
    Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667–74.CrossRefGoogle Scholar
  58. 58.
    Thurston AV, Briant SL. Aspirin and post-prostatectomy hemorrhage. Br J Urol. 1993;71(5):574–6.CrossRefGoogle Scholar
  59. 59.
    Oprea AD, Popescu WM. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. J Cardiothorac Vasc Anesth. 2013;27(4):779–95.CrossRefGoogle Scholar
  60. 60.
    Cook-Norris RH, Michaels JD, Weaver AL, Phillips PK, Brewer JD, Roenigk RK, et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol. 2011;65(3):584–91.CrossRefGoogle Scholar
  61. 61.
    Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol. 2007;49(22):2145–50.CrossRefGoogle Scholar
  62. 62.
    Taylor GMO, Diane MD, Thevenin AMD, Devys J-MMD. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg. 2013;74(5):1367–9.CrossRefGoogle Scholar
  63. 63.
    Chou S, Eshaghian S, Lamer A, Tran H, Dohad S, Kaul S. Bridging therapy in the perioperative management of patients with drug-eluting stents. Rev Cardiovasc Med. 2009;10(4):209–18.PubMedGoogle Scholar
  64. 64.
    Savonitto S, D’Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104(3):285–91.CrossRefGoogle Scholar
  65. 65.
    Lizza BD, Kauflin MJ. Extended-infusion eptifibatide to prevent stent thrombosis in a patient undergoing orthopedic surgery. Ann Pharmacother. 2011;45(5):e28.CrossRefGoogle Scholar
  66. 66.
    Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362–7.CrossRefGoogle Scholar
  67. 67.
    Llau JV, Ferrandis R, Sierra P, Gomez-Luque A. Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vasc Health Risk Manag. 2010;6:855–67.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ibrahim M. Ali
    • 1
  • Alexander Volodarskiy
    • 2
  • Joe F. Lau
    • 3
  1. 1.Department of CardiologyNorthwell Health, Zucker School of Medicine at Hofstra/NorthwellManhassetUSA
  2. 2.Department of CardiologyNew York-Presbyterian/QueensFlushingUSA
  3. 3.Department of CardiologyZucker School of Medicine at Hofstra/Northwell, Northwell HealthManhassetUSA

Personalised recommendations